Oliver Engert Buys 1,000 Shares of Enovis (NYSE:ENOV) Stock

Enovis Corporation (NYSE:ENOV – Get Free Report) insider Oliver Engert acquired 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 10th. The stock was bought at an average price of $23.00 per share, with a total value of $23,000.00. Following the acquisition, the insider directly owned 50,640 shares of the company’s stock, valued at $1,164,720. The trade was a 2.01% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Oliver Engert also recently made the following trade(s):

Get Enovis alerts:

• On Monday, June 1st, Oliver Engert bought 1,000 shares of Enovis stock. The stock was bought at an average cost of $22.22 per share, for a total transaction of $22,220.00.
• On Friday, March 13th, Oliver Engert bought 1,000 shares of Enovis stock. The stock was bought at an average cost of $23.74 per share, for a total transaction of $23,740.00.

Enovis Trading Down 3.5%

Shares of ENOV stock traded down $0.76 on Thursday, reaching $21.21. The company had a trading volume of 1,502,415 shares, compared to its average volume of 1,011,992. The company has a current ratio of 2.04, a quick ratio of 1.05 and a debt-to-equity ratio of 0.87. The stock has a market cap of $1.22 billion, a PE ratio of 6.50 and a beta of 1.38. The company has a 50-day moving average of $24.07 and a 200-day moving average of $24.63. Enovis Corporation has a 12 month low of $20.55 and a 12 month high of $36.82.

Enovis (NYSE:ENOV – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.89 EPS for the quarter, beating analysts’ consensus estimates of $0.82 by $0.07. The company had revenue of $589.15 million during the quarter, compared to analysts’ expectations of $572.02 million. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.Enovis’s revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.81 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities analysts forecast that Enovis Corporation will post 3.65 earnings per share for the current year.

Analyst Ratings Changes

ENOV has been the subject of a number of recent analyst reports. Wall Street Zen cut Enovis from a “buy” rating to a “hold” rating in a research note on Saturday, June 6th. BTIG Research reissued a “buy” rating and issued a $39.00 price target on shares of Enovis in a report on Friday, May 22nd. Zacks Research lowered shares of Enovis from a “strong-buy” rating to a “hold” rating in a report on Monday, June 1st. William Blair started coverage on shares of Enovis in a report on Friday, April 17th. They issued an “outperform” rating for the company. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Enovis in a report on Friday, April 10th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $44.50.

Read Our Latest Research Report on ENOV

Institutional Trading of Enovis

Several hedge funds and other institutional investors have recently modified their holdings of ENOV. Rubric Capital Management LP acquired a new stake in shares of Enovis in the 3rd quarter valued at about $83,435,000. Paradigm Capital Management Inc. NY grew its stake in shares of Enovis by 70.2% during the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company’s stock worth $40,420,000 after acquiring an additional 732,917 shares in the last quarter. AQR Capital Management LLC grew its stake in shares of Enovis by 682.6% during the 2nd quarter. AQR Capital Management LLC now owns 498,317 shares of the company’s stock worth $15,627,000 after acquiring an additional 434,646 shares in the last quarter. Front Street Capital Management Inc. grew its stake in shares of Enovis by 106.1% during the 1st quarter. Front Street Capital Management Inc. now owns 746,056 shares of the company’s stock worth $16,973,000 after acquiring an additional 384,124 shares in the last quarter. Finally, Quantinno Capital Management LP grew its stake in shares of Enovis by 130.8% during the 1st quarter. Quantinno Capital Management LP now owns 604,500 shares of the company’s stock worth $13,752,000 after acquiring an additional 342,556 shares in the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Company Profile

(Get Free Report)

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.

Featured Articles

• Five stocks we like better than Enovis
• Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
• NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
• The World Cup Is Coming—These 3 Stocks Could Cash In
• Spotify’s “North Star” Outlook Was Music to Investors Ears

Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.